Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 14, Issue 1, Pages 51-65Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2014.863709
Keywords
bipolar disorder; brain-derived neurotrophic factor; cognitive performance; genetic association study; major depressive disorder; neuroimaging; neurotrophins; pharmacogenetic; schizophrenia; serum chemistry
Categories
Funding
- Abbott
- AstraZeneca
- Bristol-Myers Squibb/Otsuka
- Cephalon
- Dainippon
- Sumitomo
- Forest
- France Foundation
- GlaxoSmithKline
- Janssen
- Johnson and Johnson
- Lilly
- Lundbeck
- Merck
- Neurosearch
- OrthoMcNeil
- Pfizer
- Repligen
- Sanofi
- Schering-Plough
- Servier
- Solvay
- Synosia
- Supernus Pharmaceuticals
- Takeda
- Wyeth
Ask authors/readers for more resources
Relationship between neurotrophins, especially brain-derived neurotrophic factor (BDNF) and bipolar disorder (BPD) has been widely investigated, but results have been inconsistent. BDNF polymorphism may be associated with the susceptibility to subtype BPD such as rapid cycling BPD or early onset BPD. Met allele carriers of Val66Met of BDNF gene had smaller gray matter (GM) in both patients and healthy controls, but bipolar patients carrying Met allele had better response to lithium treatment. Decreased serum/plasma BDNF levels were observed at different mood states. BDNF may interact with other systems to execute its neuroprotective effects. Overall data suggest that neurotrophins may be involved in the pathogenesis of BPD and treatment response, but the magnitude of their role needs further investigation with large sample size studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available